Trials for AstraZeneca's new 'antibody cocktail' treatment will begin in the UK - and it could prevent Covid-19 from developing for up to a year. The clinical trial will recruit 5,000 participants, which includes 1,000 people from nine sites in the UK. The UK Government has an in-principle agreement to secure access to one million doses of the antibody combination, dubbed AZD7442, if it is successful in the phase three trials. Whilst it is unclear how much the antibody treatment will cost, Sir Mene said it will be 'more expensive than vaccines', but added 'we hope to make it cost effective'. 'That is why we have procured one million doses of AstraZeneca's long-acting antibody treatment if it meets robust safety and effectiveness standards.'

Source: Daily Mail November 21, 2020 01:53 UTC